Introduction
Interleukin (IL)-6 and the cytokines of the IL-6 family are major growth factors of tumor cells in multiple myeloma (MM) Zhang et al., 1994b) . IL-6 is a proliferation factor for primary myeloma cells (Kawano et al., 1988; Klein et al., 1989) and IL-6-dependent myeloma cell lines can be obtained from patients with terminal disease (Shimizu et al., 1989; Westendorf et al., 1996; Zhang et al., 1994a) . IL-6 is produced mainly by cells of the bone marrow environment (Klein et al., 1989; Portier et al., 1991) . These cells are induced to produce IL-6 after interaction with myeloma cells (Chauhan et al., 1996; Lokhorst et al., 1994) . IL-6 binds to a membrane or soluble receptor (IL-6R) and the IL-6/IL-6R complex binds and induces the dimerization of the gp130 IL-6 transducer (Kishimoto et al., 1995) .
Other cytokines and growth factors have been shown to be myeloma cell survival factors (interferon-alpha) (Ferlin-Bezombes et al., 1998) or survival and proliferation factors (tumor necrosis factor, insulin growth factor) (Ferlin et al., 2000; Georgii-Hemming et al., 1996; Jelinek et al., 1997; Jourdan et al., 1999) .
Using macroarrays, we recently compared the expression of intercellular communication genes between myeloma cell and B cell lines and found that the gene coding for heparin-binding epidermal growth factor-like growth factor (HB-EGF) was overexpressed in some myeloma cell lines (De Vos et al., 2001) . HB-EGF is a member of the EGF family that binds to and induces the activation of two of the four members of the EGF receptor family: ErbB1 and ErbB4 (DavisFleischer and Besner, 1998; Iwamoto and Mekada, 2000) . HB-EGF is produced as a membrane molecule that can be cleaved by metalloproteinases by activation of protein kinase C or G protein-coupled receptors (Davis-Fleischer and Besner, 1998; Iwamoto and Mekada, 2000) . Membrane HB-EGF is the unique receptor for diphtheria toxin and mutated diphtheria toxin (mDT) is commonly used to block HB-EGF activity (Mitamura et al., 1995; Naglich et al., 1992) . Both membrane and soluble HB-EGF are able to bind and activate ErbB1 and ErbB4. The tetraspanin CD9 is a coreceptor of membrane HB-EGF and increases its biological activity 30-fold . Membrane heparin sulphate also binds HB-EGF and increases its activity (Davis-Fleischer and Besner, 1988; Iwamoto and Mekada, 2000) . HB-EGF is produced by numerous cells (skeletal muscle cells, epithelial cells, keratinocytes, mesangial cells, monocytes, lymphoid cells) and is involved in numerous functions in vivo: myogenesis, reproductive tract, gastrointestinal tract, renal system, urinary tract, hepatic system and wound healing (Davis-Fleischer and Besner, 1998; Iwamoto and Mekada, 2000) . It is also overproduced in various cancers (pancreas, prostate, head and neck, liver, leukemia) and may contribute to increased proliferation and metastasis of cancer cells (Davis-Fleischer and Besner, 1998; Iwamoto and Mekada, 2000) .
In the experiments described in this paper, we have investigated the role of HB-EGF and EGF receptor activation in the survival and proliferation of IL-6-dependent myeloma cell lines.
Results
Autocrine heparin-binding epidermal growth factor-like growth factor is critical for IL-6-dependent survival and proliferation of myeloma cells Using Atlas macroarrays and RT ± PCR, we showed previously that some HMCL overexpressed the HB-EGF gene as compared to EBV-transformed B cell lines (De Vos et al., 2001) . The XG-1 and XG-14 myeloma cells highly expressed the HB-EGF gene compared to XG-6 and XG-13 myeloma cells, as assayed by the macroassay technique (Table 1) or RT ± PCR (De Vos et al., 2001) . Figure 1 shows that this autocrine HB-EGF is critical for promoting the IL-6-dependent growth of XG-1 and XG-14 HMCL. Indeed, mutated diphtheria toxin (mDT), a speci®c inhibitor of HB-EGF (Kaefer et al., 2000) , signi®cantly (P50.05) decreased the IL-6-induced proliferation of these two HMCLs. It did not signi®cantly (P50.05) inhibit the proliferation of XG-6 and XG-13 HMCL (Figure 1 ) in agreement with their lower level of expression of the HB-EGF gene (Table  1) . The inhibitory eect of mDT was reversed by adding an excess of recombinant HB-EGF, indicating that inhibition was not due to non-speci®c toxicity of mDT (Figure 1 ). In addition, an antibody raised against recombinant HB-EGF also signi®cantly inhibited the IL-6-dependent proliferation of XG-1 HMCL (Figure 2 ). In the following, we used mainly mDT as an HB-EGF antagonist because it was more potent and less expensive than the commercially available anti-HB-EGF neutralizing antibodies.
Annexin V staining demonstrated that mDT induced apoptosis in the XG-1 and XG-14 myeloma cell lines (Figure 3) . We found that 87% of XG-1 cells and 62% of XG-14 cells were apoptotic in the presence of 100 mg/ml mDT. The mDT-induced apoptosis was reversed by adding a large amount of recombinant HB-EGF (Figure 3 ). mDT did not increase apoptosis in XG-6 cells and XG-13 cells (Figure 3) in agreement with the lack of a statistically signi®cant blockage of the proliferation of these two cell lines (Figure 1) . Thus, the mDT-mediated inhibition of 3 H-TdR incorporation in XG-1 and XG-14 myeloma cells was due to induction of apoptosis.
CD9, a coreceptor of HB-EGF, is expressed by myeloma cells
CD9 is a member of the tetraspanin family. It binds HB-EGF through its heparin-binding domain and dramatically increases the ability of HB-EGF to activate the EGF receptor and to bind diphtheria toxin (Nakamura et al., 2000) . CD9 was expressed by XG-1 and XG-14 cells (Table 1) and no regulation of membrane CD9 expression by IL-6 in myeloma cells was found (results not shown). XG-6 and XG-13 cells, that were poorly inhibited by HB-EGF antagonists, expressed CD9 marginally ( Table 1 ).
The myeloma cell growth factor activity of autocrine HB-EGF is mediated by EGF receptor (ErbB1) activation HB-EGF is known to bind two members of the EGF receptor family: ErbB1 and ErbB4 (Davis-Fleischer and Besner, 1998) . Table 1 gives the gene expression values of the four members of the EGF receptor family, as determined with ATLAS macroarrays. Myeloma cells strongly expressed the ErbB1 gene, but weakly the genes coding for the other three members. We therefore investigated whether a monoclonal antibody to ErbB1 could block the IL-6-induced proliferation of these myeloma cell lines. As shown in Figure 4 , the proliferation of XG-1 and XG-14 cells was strongly inhibited by the anti-ErbB1 antibody at a concentration (10 mg/ml) known to block the EGF-induced proliferation of the A431 human carcinoma cell line. The inhibitory eect of the anti-ErbB1 MAb was reversed by adding a large amount of recombinant HB-EGF. The proliferation of the XG-6 and XG-13 cell lines was not signi®cantly (P50.05) inhibited by the anti-ErbB1 MAb (Figure 4 ). The strong inhibition of XG-1 and XG-14 cell proliferation by the anti-ErbB1 (108) 35 (17) 37 (18) The gene expression values of HB-EGF and EGF receptor family members were determined using cytokine/receptor ATLAS macroarrays as described (De Vos et al., 2001) MAb is in agreement with their high expression of CD9, their high expression of the HB-EGF and ErbB1 genes and a marked inhibition by HB-EGF antagonists. Altogether, these data demonstrate that the IL-6-induced survival and proliferation of XG-1 and XG-14 myeloma cell lines is dependent on an autocrine CD9/ HB-EGF/ErbB1 loop.
Cooperation between IL-6 and HB-EGF triggers myeloma cell growth
We demonstrated above that the IL-6-induced survival and proliferation of the XG-1 and XG-14 myeloma cell lines is dependent on a CD9/ HB-EGF/ErbB1 autocrine loop. As shown in Figure 5 , this autocrine CD9/ HB-EGF/ErbB1 loop is not by itself sucient to promote the long-term growth of XG-1 or XG-14 myeloma cells. Indeed, without adding exogenous cytokine/growth factor, these myeloma cells apoptosed within 10 ± 14 days, in agreement with our previous observations (Gu et al., 2000) . Addition of exogenous IL-6 induced vigorous growth that was completely abolished by the B-R3 anti-gp130 IL-6 transducer. The LA-1 anti-ErbB1 MAb also inhibited the IL-6-induced growth, but less eciently than the anti-gp130 MAb. This inhibition is in keeping with the inhibition of IL-6-driven myeloma proliferation by HB-EGF antagonists reported above. Interestingly, recombinant HB-EGF also supported long-term growth of XG-1 and XG-14 myeloma cells but less eciently than IL-6. The myeloma cell growth factor activity of recombinant HB-EGF was inhibited by the anti-ErbB1 MAb. Figure 1 Inhibition of IL-6-induced myeloma cell proliferation by mutated diphtheria toxin. Myeloma cells (10 4 cells/well) were cultured for 5 days in X-VIVO 20 serum-free culture medium with 500 pg/ml of IL-6 and graded concentrations of mutated diphtheria toxin (mDT). In one culture group, 1 mg/ml of recombinant HB-EGF was added at the beginning of the culture together with 100 mg/ml of mDT and 500 pg/ml of IL-6. Results are means+s.d. of the tritiated thymidine incorporation determined on sextuplet culture wells. Results are from one experiment representative of 2 ± 4 experiments depending on the cell lines. *Indicates a statistically signi®cant dierence of the mean value compared to that of the group of cells cultured with no mDT or HB-EGF. **Indicates a statistically signi®cant dierence of the mean value compared to that of the group of cells cultured with mDT (P50.05, assayed with a Student t-test) Surprisingly, it was also completely inhibited by adding the B-R3 anti-gp130 IL-6 transducer mAb. In additional experiments, we showed that it was also inhibited by the B-E8 anti-IL-6 MAb, indicating that the myeloma cell growth activity of HB-EGF worked through an autocrine IL-6 loop (Figure 6a,b) . Using RT ± PCR, we showed here that XG-1 and XG-14 cells expressed the IL-6 gene (Figure 6c ), in keeping with our previous ®ndings that XG-1 cells produced a weak amount of autocrine IL-6 .
Discussion
In the current study we used four human myeloma cell lines whose growth is completely dependent on addition of exogenous cytokine. These cell lines were obtained by culturing primary myeloma cells from patients with extramedullary proliferation with recombinant IL-6 (Zhang et al., 1994a) .
We show for the ®rst time that HB-EGF is a new myeloma growth factor for two out of four myeloma cell lines, acting in synergy with IL-6 to promote optimal myeloma cell survival and proliferation. This is supported by the following observations:
. XG1 and XG-14 HMCL overexpressed the HB-EGF and ErbB1 genes as compared to XG-6 and XG-13 HMCL. They also overexpressed the tetraspanin CD9, which is an important coreceptor for HB-EGF, dramatically increasing its biological activity . . The exogenous IL-6-induced growth of XG-1 and XG-14 myeloma cell lines was abrogated by HB-EGF antagonists. . Recombinant HB-EGF was able to support the long-term growth of XG-1 and XG-14 myeloma cells in the absence of exogenous IL-6 and this growth was inhibited by anti-ErbB1 MAb but also by anti-gp130 IL-6 transducer or anti-IL-6 MAb.
These observations can be summarized in the scheme depicted in Figure 7 . The two myeloma cell lines XG-1 and XG-14 produced HB-EGF and IL-6 but the concentration of these autocrine cytokines alone was likely too low to support the survival and proliferation of myeloma cells. We previously showed that this is the case for IL-6. Indeed, XG-1 cells produced about 0.5 pg/10 5 cells/24 h of IL-6, an IL-6 amount 100 times lower than the IL-6 amount inducing half maximal proliferation of XG-1 cells . Regarding HB-EGF, there is no commercially available kit to determine the amount of autocrine HB-EGF produced by myeloma cells, but one may assume that the autocrine HB-EGF production is also weaker than the amount of recombinant HB-EGF (100 ng/ml) necessary to promote myeloma cell growth Although these autocrine cytokines cannot support the growth of the XG-1 and XG-14 myeloma cells by themselves, they are critical for the triggering of myeloma cell growth by exogenous cytokine. Autocrine HB-EGF cooperates with recombinant IL-6 and reciprocally, autocrine IL-6 cooperates with recombinant HB-EGF. These data suggest a synergy at the level of the gp130 and ErbB1 transducting elements and transduction pathways as recently demonstrated with the T47D breast cancer cell line (Badache and Hynes, 2001) . Indeed, the increase in cell motility of T47D cells by IL-6 was associated with MAP kinase activation and was inhibited by anti-ErbB1 antagonists. It was suggested in this study that an autocrine activation of ErbB1 in T47D cells provides a scaold for signaling molecules, making them locally available for activation by IL-6. In another study using the LNCaP prostate cancer cell line, the gp130 IL-6 transducer could be coimmunoprecipitated with the ErbB2 and ErbB3 members of the EGF receptor family (Qiu et al., 1998) and the IL-6-induced MAP kinase activation was dependent on transactivation of ErbB2 (Qiu et al., 1998) . We have been unable so far to show an association of the gp130 IL-6 transducer and the ErbB1 receptor in myeloma cells using immunoprecipitation. This may be explained by the low number of receptors on the cell membrane of myeloma cells, previously estimated at 1000 gp130 IL-6 transducer molecules per cell (Gaillard et al., 1997) . This may be also explained by an indirect interaction via CD9 molecule resulting in a low anity gp130/ HB-EGF/CD9/ErbB1 complex.
The cooperation between the HB-EGF/ErbB1 and IL-6/gp130 pathways to promote myeloma cell growth Figure 2 Inhibition of IL-6-induced myeloma cell proliferation by anti-HB-EGF antibodies. XG-1 myeloma cells (10 4 cells/well) were cultured for 5 days in X-VIVO 20 serum-free culture medium with 500 pg/ml of IL-6 and graded concentrations of a goat neutralizing anti-HB-EGF antibody or 50 mg/ml of puri®ed goat Ig. In one culture group, 1 mg/ml of recombinant HB-EGF was added at the beginning of the culture together with 50 mg/ml of the anti-HB-EGF antibody and 500 pg/ml of IL-6. Results are means+s.d. of the tritiated thymidine incorporation determined on sextuplet culture wells. Results are of one experiment representative of three experiments. *Indicates a statistical dierence of the mean value compared to that of the group of cells cultured with no anti-HB-EGF antibody or HB-EGF. **Indicates a statistically signi®cant dierence of the mean value compared to that of the group of cells cultured with anti-HB-EGF (P50.05, assayed with a Student t-test) was demonstrated in two out of four myeloma cell lines that produced HB-EGF and expressed ErbB1. In the other two cell lines, XG-6 and XG-13, this cooperation is not observed probably because these cells expressed HB-EGF, ErbB1 and CD9 poorly. It is important to investigate whether this myeloma cell growth factor activity of HB-EGF demonstrated with two cell lines can be extended to patients' bone marrow plasma cells. We have shown that primary myeloma cells from some patients express the HB-EGF gene (De Vos et al., 2001) . HB-EGF may be also produced by the myeloma bone-marrow environment. Indeed this growth factor is produced by activated monocytes (Davis-Fleischer and Besner, Figure 3 Induction of myeloma cell apoptosis by HB-EGF antagonist. Myeloma cells were cultured for 2 days with 500 pg/ml of IL-6 with or without 100 mg/ml of mutated diphtheria toxin. In one group, 1 mg/ml of HB-EGF was added at the beginning of the culture together with 500 pg/ml of IL-6 and 100 mg/ml of mutated diphtheria toxin. Apoptosis was evaluated by annexin V labeling and cyto¯uorometry analysis. The numbers in the panels indicate the percentage of apoptotic annexin V + cells. Results are of one experiment representative of two 1998) that are the main producers of IL-6 and IL-1 in the bone marrow of patients with multiple myeloma Portier et al., 1991 Portier et al., , 1993 . In addition, primary myeloma cells express the two coreceptors of HB-EGF, syndecan-1 and CD9 (Costes et al., 1999; Garcia-Sanz et al., 1999) , that enhance its biological activity (Davis-Fleischer and Besner, 1998) . The demonstration of an involvement of HB-EGF in the growth of primary myeloma cells could be of clinical interest. Indeed inhibitors of ErbB1 are currently being investigated in patients with solid tumors (Yang et al., 2001) . These ErbB1 inhibitors could be useful for improving the treatment of patients with multiple myeloma, possibly in combination with inhibitors of IL-6 that can block myeloma cell proliferation in vivo .
Materials and methods

Myeloma cell lines and reagents
The human myeloma cell lines (HMCL) ± XG-1, XG-6, XG-13 and XG-14 ± were obtained in our laboratory and their characteristics have been reported previously (Gu et al., 2000; Rebouissou et al., 1998; Zhang et al., 1994a) . The growth of these myeloma cell lines is strictly dependent on addition of exogenous IL-6. Upon removal of IL-6, cells progressively apoptose within 10 ± 14 days (Gu et al., 2000; Jourdan et al., 2000) . The HMCL were routinely maintained in RPMI 1640 and fetal calf serum or X-VIVO 20 culture medium (Biowittaker, Walkersville, MD, USA) and 5 ng/ml of IL-6 (a generous gift from Sandoz, Vienna, Austria). The experiments were performed in X-VIVO 20 serum-free culture medium (Biowittaker) to avoid the possible confounding eects of serum proteins with HB-EGF/EGF receptor pathways (Hirata et al., 2001) . Recombinant HB-EGF was Figure 4 The myeloma cell growth factor activity of HB-EGF is mediated through ErbB1 activation. Myeloma cells (10 4 cells/well) were cultured for 5 days in X-VIVO 20 serum-free culture medium with 500 pg/ml of IL-6 and graded concentrations of an antiErbB1 MAb (0 ± 10 mg/ml). In one culture group, 1 mg/ml of recombinant HB-EGF was added at the beginning of the culture with 10 mg/ml of the anti-ErbB1 MAb and 500 pg/ml of IL-6. Results are means+s.d. of the tritiated thymidine incorporation determined on sextuplet culture wells. *Indicates a statistically signi®cant dierence of the mean value compared to that of the group of cells cultured with no anti-ErbB1 or HB-EGF. **Indicates a statistically signi®cant dierence of the mean value compared to that of the group of cells cultured with anti-ErbB1 (P50.05, assayed with a Student t-test) purchased from R&D Systems (Minneapolis, MN, USA), mutated diphtheria toxin (mDT, CRM197), an inhibitor of HB-EGF, from Sigma (St. Louis, MO, USA), the neutralizing antibody to HB-EGF from R&D Systems and the neutralizing LA-1 monoclonal antibody (MAb) to ErbB1 receptor from UBI (Lake Placid, NY, USA), puri®ed goat polyclonal immunoglobulins (Ig) from TEBU (Le Perray-enYvelines, France), the PE-conjugated anti-human CD9 MAb and isotype-matched control MAb from Immunotech (Marseille, France). The B-R3 neutralizing anti-gp130 IL-6 transducer MAb was obtained by our group .
Intercellular signaling gene expression in myeloma cells
The expression of 268 genes coding for intercellular signaling proteins was evaluated in myeloma cell lines and EBVtransformed cell lines with the cytokine/receptor Atlas macroarray (ClonTech, Palo Alto, CA, USA). The methodology and the major ®ndings have been described previously (De Vos et al., 2001) . Gene expression data are available from our Web site at http://www.u475.montp.inserm.fr/JDV/ liensmyelo.htm.
Flow cytometry analysis
The expression of CD9 was evaluated by incubating 5610 5 myeloma cells with 0.5 mg of an anti-human PE-conjugated CD9 MAb or a PE-conjugated control murine MAb that recognizes no human antigen in PBS containing 30% human AB serum (to block Fc receptors) at 48C for 30 min. The percentage of labeled cells and the mean uorescence intensity (MFI) were determined with a FACScan¯ow cytometry (Becton Dickinson, Mountain View, CA, USA).
Cell proliferation assay
Cells were cultured for 5 days in 96-well¯at-bottomed microtiter plates at 10 4 cells/well in X-VIVO 20 serum-free culture medium. Various concentrations of cytokines or growth factors or inhibitors of cytokine/growth factor were added at the beginning of the culture in six culture wells per group. At the end of the culture, cells were pulsed with tritiated thymidine (Amersham Pharmacia Biotech, Orsay, France) for 12 h, harvested and counted as reported previously (De Vos et al., 2000) . 5 cells/ml in X-VIVO 20 serum-free culture medium with 10 mg/ml of a murine MAb recognizing no human antigen and either with no cytokine, 500 pg/ml of IL-6 (a and c) or 100 ng/ml of recombinant HB-EGF (b and d). In some culture groups, 10 mg/ml of the neutralizing B-R3 anti-gp130 IL-6 transducer MAb or of the neutralizing LA-1 anti-ErbB1 MAb were added. Every 3 ± 4 days, viability and cell counts were assayed and cells were replated at 2610 5 cells/ml with fresh culture medium containing, for each group, the initial cytokine and/or cytokine inhibitor concentrations. Results are the cumulative cell numbers generated in the culture of one experiment representative of three
Myeloma cell long-term growth
To investigate the eects of HB-EGF or IL-6 on the longterm growth of myeloma cells, cells were washed twice with culture medium, incubated for 5 h at 378C in X-VIVO 20 and washed again once. They were then cultured at a cell concentration of 2610 5 cells/ml with 10 mg/ml of a murine MAb that recognizes no human antigen and with HB-EGF (50 ng/ml) or IL-6 (500 pg/ml) with or without 10 mg/ml of the LA-1 neutralizing anti-erbB1 MAb or 10 mg/ml of the B-R3 neutralizing anti-gp130 MAb or 10 mg/ml of the B-E8 neutralizing anti-IL-6 MAb.
Detection of apoptotic cells
Myeloma cells were cultured for 3 ± 4 days in 24-well¯at-bottomed microtiter plates at 3610 5 cells/well in X-VIVO 20 culture medium with various cytokines/growth factors or inhibitors to cytokines/growth factors. At the end of the culture, cells were washed twice in PBS and suspended in Annexin-V FITC solution (Boehringer, Mannheim, Germany). Fluorescence was analysed on a FACScan¯ow cytometer.
Reverse transcriptase-polymerase chain reaction
We generated cDNA with 2 mg of total RNA using the Superscript II reverse transcriptase (Life Technologies) and oligo d(T) 12 ± 18 (Amersham Pharmacia Biotech) as primer. Each 25-ml PCR reaction contained 1 ml of the ®rst strand cDNA, 1 mM of each primer (sense and antisense), 0.2 mM of Figure 6 The myeloma cell growth factor activity of HB-EGF is dependent on an autocrine IL-6/gp130 loop. (a and b) The XG-1 (a) or XG-14 (b) myeloma cells were cultured at 2610 5 cells/ml in X-VIVO 20 serum-free culture medium with 10 mg/ml of a murine MAb recognizing no human antigen and either with no cytokine, 500 pg/ml or IL-6 or 100 ng/ml of recombinant HB-EGF. In some culture groups, 10 mg/ml of the neutralizing B-E8 anti-IL-6 MAb or of the neutralizing B-R3 anti-gp130 MAb were added. Every 3 ± 4 days, viability and cell counts were assayed and cells were replated at 2610 5 cells/ml with fresh culture medium containing, for each group, the initial cytokine and/or cytokine inhibitor concentrations. Results are the cumulative cell numbers generated in the culture of one experiment representative of two. (c) RT ± PCR analysis of IL-6 was performed on cDNA from myeloma cell lines. b2-microglobulin (b2M) ampli®cation shows the equivalence of the cDNA loading and ampli®cation. Data are representative of two independent RT ± PCRs Figure 7 Cooperation between the CD9/HB-EGF/ErbB1 and IL-6/IL-6R/gp130 pathways in triggering myeloma cell growth Oncogene Cooperation of IL-6 and HB-EGF for myeloma cell growth YD Wang et al each dNTP, 1.5 mM MgCl 2 , 16polymerase buer, 2 units of Taq polymerase (Life Technologies), and 1 mCi of [a 32 P]-dCTP (Amersham Pharmacia Biotech). The following primers were used: IL-6 5'-ATG AAC TCC TTC TCC ACA AGC GC (sense) and 5'-GAA GAG CCC TCA GGC TGG ACTG (antisense); HB-EGF 5'-TGG TGC TGA AGC TCT TTC TGG (sense) and 5'-GTG GGA ATT AGT CAT GCC CAA (antisense); b2-microglobulin (b2M) 5'-CCA GCA GAG AAT GGA AAG TC (sense) and 5'-GAT GCT GCT TAC ATG TCT CG (antisense). The sizes of the PCR products were: IL-6 (628 bp), HB-EGF (605 bp), b2M (269 bp). The ampli®cation pro®le was 1 min at 948C, 45 s at 638C (IL-6), 628C (HB-EGF) and 608C (b2M), 1 min at 728C, followed by a ®nal extension of 10 min at 728C. The cycle number was 28 for IL-6, 32 for HB-EGF, and 25 for b2M. Reaction products were electrophoresed on a 4% polyacrylamide gel, dried, and exposed to X-ray ®lm.
